Streetbeat News

Price Targets

NUE

JP Morgan analyst Michael Glick initiates coverage on Nucor (NYSE:NUE) with an Underweight rating and announces a price target of $130.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 9:20 am

QTRX

Goldman Sachs analyst Matthew Sykes upgrades Quanterix (NASDAQ:QTRX) from Neutral to Buy and raises the price target from $13 to $27.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 9:15 am

MYGN

Goldman Sachs analyst Matthew Sykes upgrades Myriad Genetics (NASDAQ:MYGN) from Sell to Buy and raises the price target from $18 to $25.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 9:14 am

RH

Telsey Advisory Group analyst Joseph Feldman has reiterated a Market Perform rating on RH (NYSE:RH) and maintained a $225 price target.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 9:08 am

HIBB

Telsey Advisory Group analyst Joseph Feldman maintains an Outperform rating on Hibbett (NASDAQ:HIBB) but lowers the price target from $80 to $70.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 9:07 am

CMRX

Baird analyst Joel Beatty has initiated coverage on Chimerix (NASDAQ:CMRX) with an Outperform rating and a price target of $7.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 8:30 am

RAIN

EF Hutton analyst Tony Butler downgrades Rain Oncology (NASDAQ:RAIN) from Buy to Hold and lowers the price target from $16 to $5.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 8:27 am

VECT

Credit Suisse analyst Tiago Fauth downgraded VectivBio Holding (NASDAQ:VECT) from Outperform to Neutral and lowered the price target from $22 to $17.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 8:23 am

GHL

Keefe, Bruyette & Woods analyst Matthew Moon has upgraded Greenhill & Co (NYSE:GHL) from Underperform to Market Perform and raised the price target from $6.5 to $15.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 8:21 am

IMVT

Chardan Capital analyst Matthew Barcus maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $21 to $32.

Portfolio Pulse from richadhand@benzinga.com

May 23, 2023 | 8:19 am